NEFH and proximal spinal muscular atrophy: These findings demonstrate that blood NfH serves as a valuable biomarker for acute disease monitoring and treatment response in early-stage SMA, but its utility appears limited in chronic SMA cases, underscoring the need to identify additional biomarkers for long-term disease management (Spicer et al. [43]).